Ascendis Pharma A/S
YUVIWEL
achondroplasia
Resolved
7days ago
FDA decision · ~ Jun 30, 2026 estimated
What's at stake
The FDA's approval decision on YUVIWEL for achondroplasia is due ~ Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“Ascendis expects to make YUVIWEL available through prescribing physicians in the United States during the early part of the second quarter of 2026.”